Michael Ken Woodward
Instituto Grifols SA
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Michael Ken Woodward as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:02 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT00323856 · Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia AGrifols Biologicals, LLC · completed · Severe Hemophilia A · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:02 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:02 UTC. The ranking covers the 200 most relevant of 5 PubMed records, and a shared surname and initials can bring in a namesake. All 5 on PubMed
- Preoperative antithrombin supplementation in cardiac surgery: a randomized controlled trial.J Thorac Cardiovasc Surg · 201339 citationsRCR 1.8
- 25 citationsRCR 1.0
- 12 citationsRCR 1.4
- Efficacy, safety, and pharmacokinetics of intramuscular hepatitis B immune globulin, Igantibe, for the prophylaxis of viral B hepatitis after liver transplantation.Dig Liver Dis · 201011 citationsRCR 0.4
- Plasma exchange with albumin replacement and disease progression in amyotrophic lateral sclerosis: a pilot study.Neurol Sci · 20223 citationsRCR 0.3